期刊
MBIO
卷 11, 期 4, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/mBio.01806-20
关键词
COVID-19; SARS-CoV-2; antibiotic resistance; coinfection; secondary bacterial infection
类别
资金
- NIH [K22AI127473, UL1TR001881]
- Cystic Fibrosis Foundation [JORTH17F5, JORTH19I0, JORTH19P0]
Coronavirus disease 2019 (COVID-19) is the greatest pandemic of our generation, with 16 million people affected and 650,000 deaths worldwide so far. One of the risk factors associated with COVID-19 is secondary bacterial pneumonia. In recent studies on COVID-19 patients, secondary bacterial infections were significantly associated with worse outcomes and death despite antimicrobial therapies. In the past, the intensive use of antibiotics during the severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic led to increases in the prevalence of multidrug-resistant bacteria. The rising number of antibiotic-resistant bacteria and our decreasing capacity to eradicate them not only render us more vulnerable to bacterial infections but also weaken us during viral pandemics. The COVID-19 pandemic reminds us of the great health challenges we are facing, especially regarding antibiotic-resistant bacteria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据